Skip to main content
SpringerLink
Log in

Serum Tumor Marker CA 15.3 and Stage are the Two Most Powerful Predictors of Survival in Primary Breast Cancer

  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

The purpose of this prospective study was to evaluate the usefulness of tumor marker CA 15.3 determined at the time of primary diagnosis as a prognostic factor in breast cancer. The power of CA 15.3 to predict survival was compared to established prognostic markers, namely stage, grade, receptor status, and histological subtype. CA 15.3 was abnormal (≥30 U/ml) in 31 (11%) of the 272 patients. During the median follow-up of 9.8 years, 83 (31%) of the patients died of breast cancer. The disease-specific survival at 5 years were 86 and 45% with normal and abnormal CA 15.3 values, respectively (p < 0.00005). When using univariate analysis, tumor size, nodal status, M status, stage, tumor grade, and CA 15.3 were significantly related to patient outcome. In the regression analysis, stage (p = 0.00023) and CA 15.3 (p = 0.00006) were prognostic factors for survival. These results indicate that CA 15.3 can predict survival in primary breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Clark GM: Prognostic and predictive factors. In: Harris JR, Lippman ME, Morrow M, Hellman S (eds) Diseases of the Breast. Lippincott-Raven, Philadelphia, 1996, pp 461–485

    Google Scholar 

  2. Tumor Marker Expert Panel: Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. J Clin Oncol 14: 2843–2877, 1996

    Google Scholar 

  3. Stearns V, Yamauchi H, Hayes DH: Circulating tumor markers in breast cancer: accepted utilities and novel prospects. Breast Cancer Res Treat 52: 239–259, 1998

    Google Scholar 

  4. Sobin LH, Wittekind CH: TNM Classification of Malignant Tumours. Wiley-Liss, New York, 1997, pp 123–130

    Google Scholar 

  5. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457–481, 1958.

    Google Scholar 

  6. Peto R, Peto J: Asymptomatically efficient rank invariant test procedures. J Roy Statist Soc Ser A 135: 185–198, 1972

    Google Scholar 

  7. Cox DR: Regression models and life tables with discussion. J Stat Soc B 34: 187–192, 1972

    Google Scholar 

  8. EGRET for Windows: Software for the Analysis of Bio-medical and Epidemiological Studies. User Manual. Cytel Software Corporation, Cambridge, MA, 1999

  9. SPSS® Base 9.0: Applications Guide. SPSS Inc., Chicago, IL, 1999

    Google Scholar 

  10. Tumor Marker Expert Panel: 1997 update of recommendations for the use of tumor markers in breast and colorectal cancer. J Clin Oncol 16: 793–795, 1998

    Google Scholar 

  11. Shering SG, Sherry F, McDermott EW, O'Higgins NJ, Duffy MJ: Preoperative CA 15-3 concentrations predict out-come of patients with breast cancer. Cancer 83: 2521–2527, 1998

    Google Scholar 

  12. Molina R, Jo J, Filella X, Zanon G, Pahisa J, Muñoz M, Farrus B, Latre ML, Escriche C, Estape J, Ballesta AM: c-erbB-2 oncoprotein, CEA, and CA 15.3 in patients with breast cancer: prognostic value. Breast Cancer Res Treat 51: 109–119, 1998

    Google Scholar 

  13. Wojtacki J, Dziewulska-Bokiniec A, Kowalski DM, Zoltowska A, Ciesielski D, Suszko M: Pretreatment values of serum CA 15-3 antigen related to prognostic factors in breast cancer patients. Neoplasma 43: 225–229, 1996

    Google Scholar 

  14. Tampellini M, Berruti A, Gerbino A, Buniva T, Torta M, Gorzegno G, Faggiuolo R, Cannone R, Farris A, Destefanis M, Moro G, Deltetto F, Dogliotti L: Relationship between CA 15-3 serum levels and disease extent in predicting overall sur-vival of breast cancer patients with newly diagnosed metastatic disease. Br J Cancer 75: 698–702, 1997

    Google Scholar 

  15. Molina R, Zanón G, Filella X, Moreno F, Jo J, Daniels M, Latre ML, Giménez N, Pahisa J, Velasco M, Ballesta AM: Use of serial carcinoembryonic antigen and CA 15.3 assays in detecting relapses in breast cancer patients. Breast Cancer Res Treat 36: 41–48, 1995

    Google Scholar 

  16. Hayes DF, Kaplan W: Evaluation of patients after primary therapy. In: Harris JR, Lippman ME, Morrow M, Hellman S (eds) Diseases of the Breast. Lippincott-Raven, Philadelphia, 1996, pp 629–647

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncology, Kuopio University Hospital, Finland

    Eero Juha Kumpulainen, Riitta Johanna Keskikuru & Risto Tapio Johansson

Authors
  1. Eero Juha Kumpulainen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Riitta Johanna Keskikuru
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Risto Tapio Johansson
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kumpulainen, E.J., Keskikuru, R.J. & Johansson, R.T. Serum Tumor Marker CA 15.3 and Stage are the Two Most Powerful Predictors of Survival in Primary Breast Cancer. Breast Cancer Res Treat 76, 95–102 (2002). https://doi.org/10.1023/A:1020514925143

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1020514925143

Search

Navigation